Chemed's Mixed Q4 2025: VITAS Grows, Roto-Rooter Struggles
Event summary
- Chemed's Q4 2025 revenue was $639.3 million, essentially flat compared to Q4 2024.
- VITAS segment saw a 1.9% increase in net patient revenue and a 6.0% increase in admissions.
- Roto-Rooter segment reported a 3.7% decrease in revenue and a 21.1% decline in adjusted EBITDA.
- Chemed repurchased 400,000 shares of stock for $174.6 million in Q4 2025.
- Full-year 2026 guidance projects VITAS revenue growth of 5.5% to 6.5% and Roto-Rooter revenue growth of 3.0% to 3.5%.
The big picture
Chemed's Q4 2025 results highlight the contrasting fortunes of its two main segments: VITAS Healthcare, which continues to grow despite regulatory pressures, and Roto-Rooter, which faces declining revenue and margins. The company's strategic focus on share repurchases and projected growth for 2026 will be critical in maintaining investor confidence amid these segment dynamics.
What we're watching
- Segment Performance
- Whether VITAS can sustain its growth trajectory amid Medicare Cap challenges and how Roto-Rooter will address its declining revenue and margins.
- Financial Guidance
- The pace at which Chemed can achieve its projected revenue growth for both VITAS and Roto-Rooter in 2026.
- Shareholder Returns
- How Chemed's share repurchase program will impact its financial flexibility and long-term strategic investments.
Related topics